Congress Materials – Fall Clinical Dermatology Conference (FCDC 2026)

Durability of Icotrokinra Effect in Participants With Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Pooled Analysis of One-Year Outcomes From the Phase 3 ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 Trials

April W. Armstrong, Iain B. McInnes, Linda Stein Gold, Mark G. Lebwohl, Ofelia Reyes-Servin, Ya-Wen Yang, Soumya D. Chakravarty, Charles Iaconangelo, Kellen Cresswell, Tasneam Shagroni, Sarah Ofori, Karissa Lozenski, Joseph F. Merola

This document will be available on Oct 8th 2026

Durability of Response to Icotrokinra in Adults and Adolescents With Moderate-to-Severe Plaque Psoriasis: 2-Year ICONIC-LEAD Findings

This document will be available on Oct 9th 2026

Durability of Systemic and Skin Pharmacodynamic Responses With Icotrokinra in Moderate-to-Severe Plaque Psoriasis: Phase 3 ICONIC-LEAD Week 52 Results

J Angsana, C Hill, E Chen, S Nischal, D Balakrishna, L Tomsho, ME Polak, C Sisk, A Kannan, C DeKlotz, M Miller-Kassamali, (REMOVE: J Cafone), Y-W Yang, P Newbold, CA Cuff, D Waterworth, N Sabins, JG Krueger, A Pinter, R Bissonnette

This document will be available on Oct 8th 2026

Effects of Glucagon-Like Peptide-1 (GLP-1)–Based Medications on Icotrokinra Efficacy, Safety, and Pharmacokinetics: Pooled Results Across ICONIC Phase 3 Studies

Linda Stein Gold, April W. Armstrong, Jennifer Soung, Ronald B. Vender, Andrew E. Pink, Lea Kephart, Bassey Effiom Edem, Ofelia Reyes-Servin, Shu Li, Ya-Wen Yang, Christopher Russo, Benjamin Ungar, Mark G. Lebwohl

This document will be available on Oct 8th 2026

Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis Across APEX Participant Subgroups

Philip J Mease, Christopher T Ritchlin, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, April W. Armstrong, Karissa Lozenski, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde

This document will be available on Oct 8th 2026

Long-term Durability and Safety of the Targeted Oral Peptide Icotrokinra for High-Impact Site Psoriasis: 2-year Findings From the ICONIC-TOTAL Randomized Controlled Trial

Richard B. Warren, Eingun James Song, Edward Lain, Joseph F. Merola, Matthias Hoffmann, Robert Bissonnette, Yu-Huei Huang, Amy Paller, Jessica H. Rubens, Melissa Larick, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Cynthia M. C. DeKlotz, Melinda Gooderham

This document will be available on Oct 8th 2026

Patient Preferences for Systemic Psoriasis Treatments: Initial findings from a multi-country Discrete Choice Experiment

This document will be available on Oct 8th 2026

Prior Treatment Patterns, Clinical Characteristics, and Disease Burden Among Patients Initiating Icotrokinra

This document will be available on Oct 8th 2026

Unmet Needs and Disease Burden: Perspectives from Adults with Psoriasis and Clinicians treating Psoriasis in Brazil

This document will be available on Oct 8th 2026

VISIBLE Cohort A: Guselkumab Skin Clearance and Patient-Reported Outcomes Across Skin and Joint Symptoms Through Week 100 in Participants With Moderate-to-Severe Plaque Psoriasis Across All Skin Tones

Andrew Alexis, Adrian O Rodriguez, Geeta Yadav, Stephen K Tyring, Olivia Choi, Theodore Alkousakis, Daphne Chan, Tony Ma, Maxwell Sauder, Javier Alonso-Llamazares, Seemal R Desai

This document will be available on Oct 8th 2026